CN108379327A - A kind of anaesthetic and its preparation process for treating nose-nasosinusitis - Google Patents

A kind of anaesthetic and its preparation process for treating nose-nasosinusitis Download PDF

Info

Publication number
CN108379327A
CN108379327A CN201810484805.6A CN201810484805A CN108379327A CN 108379327 A CN108379327 A CN 108379327A CN 201810484805 A CN201810484805 A CN 201810484805A CN 108379327 A CN108379327 A CN 108379327A
Authority
CN
China
Prior art keywords
parts
anaesthetic
nasosinusitis
drying
gallic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810484805.6A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFILIATED HOSPITAL OF INNER MONGOLIA UNIVERSITY FOR NATIONALITIES
Original Assignee
AFFILIATED HOSPITAL OF INNER MONGOLIA UNIVERSITY FOR NATIONALITIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFFILIATED HOSPITAL OF INNER MONGOLIA UNIVERSITY FOR NATIONALITIES filed Critical AFFILIATED HOSPITAL OF INNER MONGOLIA UNIVERSITY FOR NATIONALITIES
Priority to CN201810484805.6A priority Critical patent/CN108379327A/en
Publication of CN108379327A publication Critical patent/CN108379327A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285—Aucklandia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/634—Forsythia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a kind of drug and its preparation process, i.e., a kind of anaesthetic and its preparation process for treating nasosinusitis.It is characterized in that：The raw material medicaments in part by weight proportioning of this drug is 1-2 parts of gallic acid, 120-150 parts of dianthus superbus.The preparation method of this drug is：By the aerial part of fresh dianthus superbus, impurity elimination is cleaned, after vacuum freeze drying, takes 120-150 parts of dianthus superbus, 1-2 parts of gallic acid by weight, mixes, and drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.Advantage is：With heat-clearing, removing toxic substances, detumescence, analgesic, convergence, the medicinal material auxiliary gallic acid treatment nasosinusitis for improving voxel, ingredient mutual reinforcement between mutually makes in prescription, it gives full play to gallic acid antibacterial, anti-inflammatory, kill viscous effect, then it obtains high to nasosinusitis treatment cure rate, it is uneasy to recur, the low Prescription of Mongolian Medicine of side effect.

Description

A kind of anaesthetic and its preparation process for treating nose-nasosinusitis
Technical field
The present invention relates to a kind of drug and its preparation process, i.e., a kind of anaesthetic and its preparation process for treating nose-nasosinusitis.
Background technology
Nose-nasosinusitis is the name of disease of doctor trained in Western medicine, and rhinitis refers to nasal cavity, inflammation existing for bronchia mucosal, and nasosinusitis refers to nasal sinus Inflammation existing for mucous membrane continues, nasosinusitis not only secondary rhinitis, but also usually companion because the mucous membrane of nasal cavity and nasal sinus adjoins Have a rhinitis, therefore it be known as nose-nasosinusitis, symptom have nasal obstruction, rhiocnesmus, rhinorrhea, giddy, headache, toothache, abundant expectoration, cough, Hyposphresia etc..Nose-nasosinusitis is a kind of common rhinopathy, and in the majority with chronic person, pathogenic factor has infection, Rhino Sinus compound operation Anatomical structure makes a variation and obstruction, primary or secondary fibre function obstacle, mucociliary structure and function obstacle, immune function Disorderly, adjacent organs infection diffusion etc..The drug therapy of nose-nasosinusitis includes mainly anti-inflammatory, antiallergy, promotes mucous membrane fine Hair transmission changes immunity of organism load defect and traditional Chinese medical herbal treatment etc..Infection is the primary pathogenesis of nose-nasosinusitis, antibiosis Element is always the choice drug of nose-nasosinusitis drug therapy, but antibiotic easy tos produce drug resistance.Other pathogenic factors are current Doctor trained in Western medicine cannot be effected a radical cure effectively, and medical expense is high.
General cue-the nasosinusitis of Chinese medicine is known as allergic rhinitis, has a stuffy nose and sneezes or chronic rhinitis.Chinese medicine thinks nose-nasosinusitis mostly because of viscera function Imbalance, along with catching cold, perverse trend is invaded nose key and is caused.It, can be by improving patient under the guidance of traditional Chinese medical theory system Constitution adjusts tonifying lung, spleen, three dirty function of kidney, and strong three is dirty, to play the role of prevention and resist disease and evil.But traditional Chinese medical doctor Pathogenesis and cause of disease opinion to nose-nasosinusitis differ, the principle of reatment and therapeutic scheme for keeping the treatment disease ununified, Without generally acknowledged diagnostic criteria and criterion of therapeutical effect.In contrast, Mongolian medicine is more unified to the understanding and principle of reatment of the illness.It is covering Under medical theoretical system, it is believed that nose-nasosinusitis belongs to sub- agate disease scope, is a kind of disease caused by sub- agate mythimna separata intrusion intracerebral Disease, Xi La are the major endogeneous for causing this disease, and external cause is the positive smart consume of human body, excessive fatigue, voxel weakness, wind and suffer from cold and sub- Agate worm, which is taken advantage of a weak point in opponent's defence, invades nose.Principle of reatment one is mythimna separata to be killed, heat-clearing, analgesic, i.e. antibacterial, anti-inflammatory；Second is that improve voxel, i.e., Correct three imbalances, conditioning, the strong vital organs of the human body.Mongolian medicine has original understanding and unified therapy to nose-nasosinusitis, delays Symptom is solved, pathogeny is eradicated, therapeutic effect is good, and medical expense is low, has no toxic side effect, and has very strong clinical generalization value.
It has been investigated that anaesthetic, during treating nose-nasosinusitis, gallic acid contained in medicinal material is main effective One of ingredient.Gallic acid has the pharmacological actions such as anti-inflammatory, antibacterial, anti-oxidant, protection is cardiovascular, antitumor, in other medicinal materials Or under the auxiliary of ingredient, synergistic effect, relatively high to the cure rate of nose-nasosinusitis illness, effect is relatively good.How further to carry To the therapeutic effect of nose-nasosinusitis, be modern Mongolia Medicine development is worth research and inquires into gallic acid in high and performance mongolian medicine Project.
Invention content
The purpose of the present invention is developing one kind with gallic acid to coordinate, the treatment of nose-nasosinusitis is controlled with higher More the anaesthetic prescription of rate and better healing effect.
It is a further object of the present invention to provide a kind of preparation processes of anaesthetic that treating nose-nasosinusitis.
Above-mentioned purpose is realized by following technical scheme：A kind of anaesthetic for treating nose-nasosinusitis is provided, its main feature is that： The raw material medicaments in part by weight proportioning of this drug is 1-2 parts of gallic acid, 120-150 parts of dianthus superbus.
The preferred embodiment of above-mentioned formula material medicine by weight ratio is：2 parts of gallic acid, 150 parts of dianthus superbus.
18-36 parts with pomegranate extraction medicinal extract of 1-2 parts of the gallic acid substitutes.
1-2 parts of the gallic acid extracts 15-30 parts of replacements of medicinal extract with myrobalan.
1-2 parts of the gallic acid, 120-150 parts of dianthus superbus, be added 50-75 parts of nutmeg, 50-75 parts of Rhododendron molle, 40-50 parts of fructus piperis longi, 40-50 parts of Fructus Forsythiae.
50-75 parts of root of Aucklandia lappa Decne, 120-150 parts of safflower, black is added in 1-2 parts of the gallic acid, 120-150 parts of dianthus superbus 50-75 parts of cloud perfume (or spice), 50-75 parts of rhizoma nardostachyos.
50-75 parts of radix aconiti agrestis, 50-75 parts of Moschus, wheat is added in 1-2 parts of the gallic acid, 120-150 parts of dianthus superbus 50-75 parts of winter, when 50-75 parts of medicine.
A kind of preparation process of the anaesthetic for treating nose-nasosinusitis：By the aerial part of fresh dianthus superbus, impurity elimination is cleaned, After vacuum freeze drying under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature, by weight Part takes 120-150 parts of dianthus superbus, 1-2 parts of gallic acid, mixes, and drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.
The beneficial effects of the invention are as follows：It is not eaten with the medicinal material auxiliary of heat-clearing, removing toxic substances, detumescence, analgesic, convergence, conditioning voxel Sub- acid treatment nose-nasosinusitis.Ingredient mutual reinforcement between mutually makes in prescription, gives full play to gallic acid antibacterial, anti-inflammatory, kills viscous effect, after And obtain, uneasy to recur, side effect low Prescription of Mongolian Medicine high to nose-Nasosinusitis therapy cure rate.
Specific implementation mode
The first embodiment：By the aerial part of fresh dianthus superbus, impurity elimination is cleaned, in -30 DEG C of pre-freeze junction temperature, 1 drying Time 3h takes 120-150 parts of dianthus superbus, nutgall by weight under conditions of 2 40 DEG C of drying temperatures after vacuum freeze drying 1-2 parts of acid, preferably 150 parts of dianthus superbus, 2 parts of gallic acid, mixing, drying and crushing sieve with 100 mesh sieve, and water is tuned into ball.Adult often takes 2-3g, 2-3 times a day.
Sub- agate disease is theoretically divided into Bai Yama, Hei Yama, spends three type of sub- agate by Mongolian medicine.Mongolian medicine thinks that Bai Yama diseases are Ya Ma Armyworm initial stage invades meninx, causes bar, up to dry disorder, to hinder caused by affected part QI-blood circulation；Hei Yama diseases are that sub- agate armyworm sucks brain Film causes uncommon drawing disorderly, hinders caused by affected part QI-blood circulation；It is to cause three imbalances after sub- agate armyworm enters brain to spend sub- agate disease, Seven elements are impaired, are oozed with yellow water and forehead and intranasal portion etc. are given birth to sore and caused.Therefore this prescription in selection process to sub- agate disease Three types have carried out following experimental study.
The foundation of mouse nose-nasosinusitis experimental model：In January, 2016 in December, 2016 is attached in National University of the Inner Mongol Belonging to 20 patients that hospital's Mongolian medicine's ear-nose-throat department is diagnosed as sub- agate disease, wherein Bai Yama diseases 6, spend sub- agate 7 at Hei Yama 7, In nasal endoscopes downlink nasal sinus opening art, excision sieve steeps, and the schneiderian membrance on sieve bubble is isolated under operating table, it is big to be cut into about 3mm × 3mm Small, normal saline flushing collects mucous membrane surface free bacterium.It presses《National clinical examination operating instruction》It is inoculated with, detached, use hand Engineering method and full automatic microorganism assessing instrument carry out Bacteria Identification, are cultivated in MH culture mediums.The preceding sterile saline of inoculation is dilute Bacterial concentration is released to 1.0 × 109CFU/mL.The notch for being a 5mm after mouse anesthesia in bridge of the nose center, starts skin to the right Valve scrapes bone 3mm with micro-bit along nasal cavity, cuts mucous membrane and enters right side nasal cavity, Merocel highly expanded styptic sponges carry out nasal cavity It blocks, syringe extracts above-mentioned bacterium solution 0.1mL and is slowly injected into the side nasal cavity.
Mouse is randomly divided into 5 groups, every group 8, i.e. control group, model group, gallic acid group, antibiotic group and anaesthetic prescription Group, antibiotic group select macrolide antibiotics clarithromycin, and the production method of anaesthetic prescription group is by the ground of fresh dianthus superbus Upper part, impurity elimination are cleaned, the vacuum under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature It after freeze-drying, takes 150 parts of dianthus superbus, 2 parts of gallic acid by weight, mixes, drying and crushing is sieved with 100 mesh sieve, mixed to obtain the final product. After modeling 4 weeks, anaesthetic prescription group gastric infusion 0.1mg, gallic acid group, antibiotic group distinguish gastric infusion 0.4ml, control group Give isometric physiological saline with model group, continuous 7d, last dose for 24 hours after, collect mice serum and nasal mucosa, use In subsequent detection.
1 mice serum superoxide dismutase of table（SOD）Activity, malonaldehyde（MDA）It is active in content and nasal mucosal tissue Oxygen（ROS）Content detection result（`x ± s, n=8）
Note：Compared with the control group##P ＜ 0.01；Compared with model group*P ＜ 0.05,**P ＜ 0.01；Compared with anaesthetic prescription group△P ＜ 0.05,△△PP ＜ 0.01.
It is obtained from Analysis of test results：Compared with the control group, model group SOD in Mice activity significantly reduces（P ＜ 0.01）, it is 0.5 times of control group；MDA and ROS contents significantly increase（P ＜ 0.01）, it is 2.69 and 2.17 times of control group respectively.With model Group is compared, and gallic acid group and antibiotic group SOD activity have increased separately 46%（P ＜ 0. 01）With 60%（P ＜ 0.01）, MDA Content declines 27% respectively（P ＜ 0.05）With 38%（P ＜ 0.05）, ROS contents reduce 36% respectively（P ＜ 0.05）With 33%（P ＜ 0.05）.Each index variation of anaesthetic prescription group becomes apparent, and compared with model group, SOD activity increases by 92%（P ＜ 0.01）, MDA and ROS contents reduce by 52% respectively（P ＜ 0.01）With 51%（P ＜ 0.01）.
Detect nasal mucosa in inflammatory factor TNF-α, IL-6 and IL-8 protein expression level, as a result with control group ratio Compared with TNF-α, IL-6 and IL-8 contents are significantly increased in model group nasal mucosal tissue（P ＜ 0.01）.Compared with model group, do not have Gallate-based group, antibiotic group and anaesthetic prescription Zu Deng treatment groups TNF-α, IL-6 and IL-8 expressions are remarkably decreased（P ＜ 0.01）.Compared with gallic acid group, antibiotic group, anaesthetic prescription group reduces the better apparent of inflammatory factor（P ＜ 0.01）.Show that anaesthetic prescription group more can effectively inhibit inflammatory factor in mouse nasal mucosal tissue than gallic acid group, antibiotic group Expression.
All of above experimental data is indicated with `x ± s, carries out one-way analysis of variance using SPASS 15.0, LSD is examined Group difference is analyzed, P ＜ 0.05 indicate that difference is statistically significant.
The studies above can be obtained to draw a conclusion：Gallic acid or antibiotic can effectively reduce scorching in serum and nasal mucosa The expression of sex factor TNF-α, IL-6 and IL-8 reduces MDA and ROS contents, enhancement of SOD activity, and the anaesthetic studied Prescription becomes apparent from than gallic acid or effects of antibiotics, prompts anaesthetic group that can effectively inhibit mouse nasal mucosa inflammatory reaction And oxidative stress.
Preparation process experimental study：It is confirmed through experimental study, Vacuum Freezing ＆ Drying Technology can preserve medicinal material to the maximum extent The activity of effective component avoids influence of the high temperature to material, the preferably form of holding medicinal material, color and luster, quality, smell, and Medicinal material water content is low, and rehydration is good, easy to maintain.
This experiment uses electric-resistivity method to measure the eutectic temperature of dianthus superbus as -21 DEG C.By studying pre-freeze junction temperature, 1 drying Influence of the single factor tests such as time, 2 drying temperatures to dianthus superbus effective component designs single factor experiment, in the base of single factor experiment On plinth, orthogonal test is designed.Finally obtain the technological parameter of vacuum freeze drying dianthus superbus.
Single factor experiment：（1）Pre-freeze junction temperature, researches show that dianthus superbus content is higher and is the general flavone of main pharmacodynamics ingredient Amount be slowly increased with the reduction of pre-freeze junction temperature, maximum value is reached at -30 DEG C, then starts to reduce.General prefreezing Temperature is 5-10 DEG C lower than eutectic temperature, and pre-freeze junction temperature is lower, and freezing energy expenditure is bigger, is also cured the time required to lyophilization It is long, to make the energy expenditure in drying process also accordingly increase.Therefore, go out from angle that is energy saving, improving freeze-drying efficiency Hair, the pre-freeze junction temperature selected is -30 DEG C.（2）1 drying time, researches show that the increase with drying time, dianthus superbus contents The amount of general flavone higher and for main pharmacodynamics ingredient is stepped up, and when 1 drying time is 4h, the amount of general flavone reaches most It is high.It later with the extension of drying time, gradually decreases, therefore selects 1 dry time for 4 h.（3）2 drying temperatures, Researches show that gradually rising with 2 drying temperatures, dianthus superbus content is higher and the amount of general flavone for main pharmacodynamics ingredient by Edge up height, and elevation amplitude is larger, the amount highest of general flavone at 40 DEG C.When temperature is more than 40 DEG C, with the raising of temperature, The amount of general flavone drastically declines.Therefore it is 40 DEG C to select 2 drying temperatures.
Orthogonal test：According to single factor exploration as a result, selected pre-freeze junction temperature（A）, 1 drying time（B）, 2 dryings Temperature（C）As three factors of investigation, each factor respectively takes three levels, using L9（34）Orthogonal test table.
2 dianthus superbus vacuum freeze drying orthogonal test of table is horizontal
The Orthogonal Experiment and Design and result of 3 dianthus superbus vacuum freeze drying of table
By orthogonal experiments it is found that influence of 3 factors investigated to general flavone content, conspicuousness size are B ＞ A ＞ C, That is 1 drying time ＞ pre-freeze junction temperature ＞, 2 drying temperatures.
4 analysis of variance table of table
The results of analysis of variance shows：A, tri- factors of B, C influence not notable（P ＞ 0.05）, with A2B1C2For preferred plan, i.e., With -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature.
Second of embodiment：18-36 parts with pomegranate extraction medicinal extract of 1-2 parts of gallic acid substitutes.Stone preferred by weight 200 parts of dryings of pomegranate simultaneously crush, and cross 80 mesh sieve, impregnate 30min and add under conditions of 40 DEG C, power 200W, frequency 40kHz of temperature 50 times of water, ultrasonic extraction 60min obtain extracting solution, and the dregs of a decoction impregnate 15min, under the same terms, then extract 2 times, merge extraction Liquid is condensed into pomegranate 36 parts of medicinal extract of extraction, and by the aerial part of fresh dianthus superbus, impurity elimination is cleaned, in -30 DEG C of pre-freeze junction temperature, 1 Secondary drying time 3h, under conditions of 2 40 DEG C of drying temperatures after vacuum freeze drying, 150 parts of dianthus superbus preferred by weight, pomegranate 36 parts of medicinal extract, mixing are extracted, drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.Adult often takes 2-3g, 2-3 times a day.
Gallic acid ultrasonic extraction process selects in pomegranate：1. single factor exploration is tested：（1）The selection of Extraction solvent, 40 DEG C of ultrasonic temperature, supersonic frequency 40kHz, ultrasonic power 500W, solid-liquid ratio 1:Under conditions of 40 is constant, respectively with water, 50% Methanol, 70% methanol, 50% ethyl alcohol, 70% ethyl alcohol be Extraction solvent, ultrasonic extraction is 30min, when as a result being extracted with water The content highest of gallic acid.（2）The selection of solid-liquid ratio, using water as Extraction solvent, ultrasound condition with（1）It is identical, feed liquid score It Wei 1:20、1:30、1:40、1:50、1:Gallic acid in 60 pairs of pomegranates extracts, as a result when solid-liquid ratio is 1:When 50, The content highest of gallic acid.（3）The selection of ultrasonic power, using water as Extraction solvent, solid-liquid ratio 1:50, respectively 200W, Gallic acid in pomegranate is extracted under the different ultrasonic powers such as 300W, 400W, 500W, when as a result ultrasonic power is 300W, Extraction effect is best.（4）The selection of ultrasonic time, at 40 DEG C, under conditions of supersonic frequency 40kHz, ultrasonic power 300W are constant, Using water as Extraction solvent, solid-liquid ratio 1:50, difference ultrasonic extraction 20min, 30min, 40min, 50min, 60min, 80min, As a result ultrasound 40min extraction effects are best.
Orthogonal test：According to single factor test preliminary examinations as a result, selected solid-liquid ratio（A）, the ultrasonic extraction time（B）, ultrasound Extract power（C）As three factors of investigation, each factor respectively takes three levels, using L9（34）Orthogonal test table arrangement tries It tests.
5 orthogonal test factor level table of table
Pomegranate dried powder is weighed, sieves with 100 mesh sieve 9 parts, every part of 1.0g, it is accurately weighed, by L9（34）It is provided in orthogonal test table Condition ultrasonic extraction, taking-up lets cool, and the weight of less loss is supplied with water, takes 0.45 μm of water system miillpore filter mistake of supernatant Filter, abandons primary filtrate, and subsequent filtrate is taken to measure gallic acid content.
6 orthogonal experiments of table（n=3）
It is A that can immediately arrive at optimum extraction scheme by table 22B3C1, according to very poor value R it is found that each factor extracts effect to gallic acid The sequence that fruit influences size is ultrasonic power C ＞ solid-liquid ratio A ＞ ultrasonic times B.
7 analysis of variance table of table
It is not notable that the results of analysis of variance shows that tri- factors of A, B, C influence（P ＞ 0.05）.Therefore pomegranate optimum extraction scheme is A2B3C1, that is, add the water of 50 times of amounts, under the conditions of 40 DEG C, power 200W, 40 kHz ultrasonic extractions of frequency, 60 min.
The computational methods of pomegranate paste-forming rate：Paste-forming rate=extraction medicinal extract（g）/ medicinal material（g）* 100%, calculate pomegranate through weighing Paste-forming rate is 18%.
Zoopery：Mouse nose-nasosinusitis experimental model is established according to the method for the first embodiment.Mouse is randomly divided into 2 groups, the production method of every group 10, i.e. anaesthetic prescription group 1 and anaesthetic prescription group 2, anaesthetic prescription group 1 are by the ground of fresh dianthus superbus Upper part, impurity elimination are cleaned, the vacuum under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature It after freeze-drying, takes 150 parts of dianthus superbus, 2 parts of gallic acid by weight, mixes, drying and crushing is sieved with 100 mesh sieve, mixed to obtain the final product； The production method of anaesthetic prescription group 2 is to take 200 parts of dryings of pomegranate by weight and crush, and crosses 80 mesh sieve, 30min is impregnated, in temperature Under conditions of 40 DEG C, power 200W, frequency 40kHz of degree, 50 times of water, ultrasonic extraction 60min is added to obtain extracting solution, the dregs of a decoction impregnate 15min under the same terms, then is extracted 2 times, merges extracting solution, pomegranate 36 parts of medicinal extract of extraction is condensed into, by the ground of fresh dianthus superbus Part, impurity elimination are cleaned, and vacuum is cold under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature Be lyophilized it is dry after, take 150 parts of dianthus superbus, pomegranate 36 parts of medicinal extract of extraction by weight, mixing, drying and crushing sieves with 100 mesh sieve, and water is tuned into Ball to obtain the final product.After modeling 4 weeks, anaesthetic prescription group 1 and anaesthetic prescription group 2 distinguish gastric infusion 0.1mg, and continuous 7d, last dose is for 24 hours Afterwards, mice serum and nasal mucosa are collected, subsequent detection is used for.
8 mice serum superoxide dismutase of table（SOD）Activity, malonaldehyde（MDA）It is active in content and nasal mucosal tissue Oxygen（ROS）Content detection result（`x ± s, n=10）
Note：The superoxide dismutase compared with anaesthetic prescription group 1 of anaesthetic prescription group 2（SOD）Activity significantly improves（P ＜ 0.05）； The malonaldehyde compared with anaesthetic prescription group 1 of anaesthetic prescription group 2（MDA）Content no significant difference（P ＞ 0.05）；Anaesthetic prescription group 2 with Anaesthetic prescription group 1 compares active oxygen in nasal mucosal tissue（ROS）Content no significant difference（P ＞ 0.05）.
Detect nasal mucosa in inflammatory factor TNF-α, IL-6 and IL-8 protein expression level, anaesthetic prescription group 1 with Anaesthetic prescription group 2 compares TNF-α in nasal mucosal tissue, IL-6 and IL-8 content no significant differences（P ＞ 0.05）.Anaesthetic prescription group 1 can effectively inhibit the expression of inflammatory factor in mouse nasal mucosal tissue with anaesthetic prescription group 2.
All of above experimental data is indicated with `x ± s, carries out one-way analysis of variance using SPASS 15.0, LSD is examined Group difference is analyzed, P ＞ 0.05 indicate no significant difference.
The studies above can be obtained to draw a conclusion：Anaesthetic prescription group 1 can effectively reduce serum with anaesthetic prescription group 2 and nose is glutinous The expression of inflammatory factor TNF-α in membrane tissue, IL-6 and IL-8 reduces MDA and ROS contents, still, anaesthetic prescription group 2 Superoxide dismutase（SOD）Activity is significantly higher than anaesthetic prescription group 1, illustrates that Punica granatum L. extract is active to enhancing SOD in Mice Function and effect are more preferable.
The third embodiment：1-2 parts of gallic acid extracts 15-30 parts of replacements of medicinal extract with myrobalan.It preferably scolds by weight Sub 150 parts of dryings simultaneously crush, and cross 80 mesh sieve, impregnate 30min and add 40 times 40% under conditions of temperature 60 C, power 300W Ethyl alcohol, ultrasonic extraction 60min obtain extracting solution, and the dregs of a decoction impregnate 15min, under the same terms, then extract 2 times, merge extracting solution, dense It shortens myrobalan into and extracts 30 parts of medicinal extract, by the aerial part of fresh dianthus superbus, impurity elimination is cleaned, in -30 DEG C of pre-freeze junction temperature, 1 drying Time 3h, under conditions of 2 40 DEG C of drying temperatures after vacuum freeze drying, 150 parts of dianthus superbus preferred by weight, myrobalan extract leaching 30 parts of cream, mixing, drying and crushing sieve with 100 mesh sieve, and water is tuned into ball.Adult often takes 2-3g, 2-3 times a day.
Gallic acid ultrasonic extraction process selects in myrobalan：1. single factor exploration is tested：Precision weighs 15 parts of myrobalan's powder, Every part of 2g is placed in 100ml conical flasks, then 15 parts of myrobalan's powder are divided into 3 groups, and every group 5 parts using gallic acid content as experiment Condition optimizing index.
9 single factor experiment arrangement of table and result
2. orthogonal test：Comprehensive single factor test screening test as a result, take tri- ultrasonic time A, concentration of alcohol B, solid-liquid ratio C water respectively It is flat to press L9（34）Orthogonal arrage is tested, using gallic acid content as the index of experimental condition optimization.Precision weighs 9 parts of matter Myrobalan's powder that amount is 2g carries out orthogonal test.
10 quadrature factor water-glass of table
Gallic acid extraction process orthogonal test arrangement in 11 myrobalan of table
12 variance analysis of table
Know that the size that three kinds of factors influence experimental result is with variance analysis by intuitively analyzing：Concentration of alcohol ＞ ultrasonic times ＞ Solid-liquid ratio, optimization test optimum extraction process are A3B2C3, i.e. ultrasonic time 60min, concentration of alcohol 40%, solid-liquid ratio 1:40.
The computational methods of myrobalan's paste-forming rate：Paste-forming rate=extraction medicinal extract（g）/ medicinal material（g）* 100%, calculate myrobalan's through weighing Paste-forming rate is 20%.
Zoopery：Mouse nose-nasosinusitis experimental model is established according to the method for the first embodiment.Mouse is randomly divided into 2 groups, the production method of every group 10, i.e. anaesthetic prescription group 1 and anaesthetic prescription group 3, anaesthetic prescription group 1 are by the ground of fresh dianthus superbus Upper part, impurity elimination are cleaned, the vacuum under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature It after freeze-drying, takes 150 parts of dianthus superbus, 2 parts of gallic acid by weight, mixes, drying and crushing is sieved with 100 mesh sieve, mixed to obtain the final product； The production method of anaesthetic prescription group 3 is to take 150 parts of dryings of myrobalan by weight and crush, and crosses 80 mesh sieve, 30min is impregnated, in temperature 60 DEG C of degree under conditions of power 300W, adds 40 times 40% of ethyl alcohol, ultrasonic extraction 60min to obtain extracting solution, and the dregs of a decoction impregnate 15min, It under the same terms, then extracts 2 times, merges extracting solution, be condensed into myrobalan and extract 30 parts of medicinal extract, by the aerial part of fresh dianthus superbus, Impurity elimination is cleaned, the vacuum freeze drying under conditions of -30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures of pre-freeze junction temperature Afterwards, take 150 parts of dianthus superbus, myrobalan to extract 30 parts of medicinal extract, mixing by weight, drying and crushing sieves with 100 mesh sieve, and water is tuned into ball to obtain the final product. After modeling 4 weeks, anaesthetic prescription group 1 and anaesthetic prescription group 3 distinguish gastric infusion 0.1mg, continuous 7d, last dose for 24 hours after, collect Mice serum and nasal mucosa are used for subsequent detection.
13 mice serum superoxide dismutase of table（SOD）Activity, malonaldehyde（MDA）It is living in content and nasal mucosal tissue Property oxygen（ROS）Content detection result（`x ± s, n=10）
Note：The superoxide dismutase compared with anaesthetic prescription group 1 of anaesthetic prescription group 3（SOD）Activity significantly improves（P ＜ 0.05）； The malonaldehyde compared with anaesthetic prescription group 1 of anaesthetic prescription group 3（MDA）Content no significant difference（P ＞ 0.05）；Anaesthetic prescription group 3 with Anaesthetic prescription group 1 compares active oxygen in nasal mucosal tissue（ROS）Content no significant difference（P ＞ 0.05）.
Detect nasal mucosa in inflammatory factor TNF-α, IL-6 and IL-8 protein expression level, anaesthetic prescription group 1 with Anaesthetic prescription group 3 compares TNF-α in nasal mucosal tissue, IL-6 and IL-8 content no significant differences（P ＞ 0.05）.Anaesthetic prescription group 1 can effectively inhibit the expression of inflammatory factor in mouse nasal mucosal tissue with anaesthetic prescription group 3.
All of above experimental data is indicated with `x ± s, carries out one-way analysis of variance using SPASS 15.0, LSD is examined Group difference is analyzed, P ＞ 0.05 indicate no significant difference.
The studies above can be obtained to draw a conclusion：Anaesthetic prescription group 1 can effectively reduce serum with anaesthetic prescription group 3 and nose is glutinous The expression of inflammatory factor TNF-α in membrane tissue, IL-6 and IL-8 reduces MDA and ROS contents, still, anaesthetic prescription group 3 Superoxide dismutase（SOD）Activity is significantly higher than anaesthetic prescription group 1, illustrates that Fructus Chebulae extract is active to enhancing SOD in Mice Function and effect are more preferable.
4th kind of embodiment：Mongolian medicine treats sub- agate disease, i.e. nose-nasosinusitis, first, to kill mythimna separata, heat-clearing, analgesic, i.e., it is anti- Bacterium, anti-inflammatory；Second is that improve voxel, that is, correct three imbalances, conditioning, the strong vital organs of the human body.It can be only achieved treating both manifestation and root cause of disease, be not easy The therapeutic effect of recurrence.According to this theory, on the basis of the first embodiment, a large amount of prescription is carried out and has selected and optimize examination It tests, finally screens to obtain following three groups of prescriptions：
One, 1-2 parts of gallic acid, 120-150 parts of dianthus superbus, 50-75 parts of nutmeg, 50-75 parts of Rhododendron molle, fructus piperis longi 40-50 Part, 40-50 parts of Fructus Forsythiae.It is preferred that 2 parts of gallic acid, 150 parts of dianthus superbus, 75 parts of nutmeg, 75 parts of Rhododendron molle, 50 parts of fructus piperis longi, Fructus Forsythiae 50 parts, drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.Adult often takes 2-3g, 2-3 times a day.
Two, 1-2 parts of gallic acid, 120-150 parts of dianthus superbus, 50-75 parts of root of Aucklandia lappa Decne, 120-150 parts of safflower, black cloud incense 50-75 parts, 50-75 parts of rhizoma nardostachyos.It is preferred that 2 parts of gallic acid, 150 parts of dianthus superbus, 75 parts of root of Aucklandia lappa Decne, 150 parts of safflower, black cloud incense 75 Part, 75 parts of rhizoma nardostachyos, drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.Adult often takes 2-3g, 2-3 times a day.
Three, 1-2 parts of gallic acid, 120-150 parts of dianthus superbus, 50-75 parts of radix aconiti agrestis, 50-75 parts of Moschus, Radix Ophiopogonis 50- 75 parts, when 50-75 parts of medicine.It is preferred that 2 parts of gallic acid, 150 parts of dianthus superbus, 75 parts of radix aconiti agrestis, 75 parts of Radix Ophiopogonis, when 75 parts of medicine, Moschus 75 parts.Moschus individually grinds to the powder, and after other medicinal material dryings crush, then mixes with Moschus fine powder, sieves with 100 mesh sieve, water is tuned into ball.At People often takes 2-3g, 2-3 times a day.
Clinical efficacy：In January, 2016 is chosen in December, 2016 in Affiliated Hospital of Inner Mongolia University for the Nationalities's Mongolian medicine's ear nose larynx Section is diagnosed as 60 patients of sub- agate disease, and wherein Bai Yama diseases 21, Hei Yama diseases 17 spend sub- agate disease 22；Male 36, Women 24；Average age（32.68±8.34）Year；Average course of disease（6.48±1.36）Year.60 patients are randomly divided into three Group presses dose continuously medication 4 weeks respectively.
The therapeutic effect data of 14 3 groups of prescriptions of table are as follows：
Note：Curative effect determinate standard is with reference to State Administration of Traditional Chinese Medicine's publication《Mongolian medicine's Illnesses Diagnoses criterion of therapeutical effect》.It cures：Nose Plug, the symptoms such as headache disappear, and the nasion, eye socket etc. tenderness sign disappears, and the auxiliary examinations result such as nasal sinus portion x-ray or CT is normal, It has no adverse reaction；Effectively：Symptom, sign and auxiliary examination result improve, and have no adverse reaction；In vain：Symptom, sign are without improvement Or it aggravates.

Claims (10)

1. a kind of anaesthetic for treating nose-nasosinusitis, it is characterised in that：The raw material medicaments in part by weight proportioning of the anaesthetic is nutgall Sour 1-2 parts, 120-150 parts of dianthus superbus.
2. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1, it is characterised in that：The bulk pharmaceutical chemicals of the anaesthetic It is 2 parts of gallic acid, 150 parts of dianthus superbus by weight ratio.
3. a kind of preparation process of anaesthetic that treating nose-nasosinusitis as claimed in claim 1 or 2, it is characterised in that：It will be fresh The aerial part of dianthus superbus, impurity elimination are cleaned, in -30 DEG C, 1 drying time 3h of pre-freeze junction temperature, the item of 2 40 DEG C of drying temperatures Under part after vacuum freeze drying, dianthus superbus, gallic acid are taken by weight, is mixed, and drying and crushing sieves with 100 mesh sieve, and water is tuned into ball.
4. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1 or 2, it is characterised in that：The gallic acid 1-2 parts are extracted 18-36 parts of replacements of medicinal extract with pomegranate.
5. a kind of preparation process of anaesthetic that treating nose-nasosinusitis as claimed in claim 4, it is characterised in that:By weight It takes 100-200 parts of dryings of pomegranate and crushes, cross 80 mesh sieve, impregnate 30min, in 40 DEG C, power 200W of temperature, frequency 40kHz's Under the conditions of, adding 50 times of water, ultrasonic extraction 60min obtains extracting solution, and the dregs of a decoction impregnate 15min, under the same terms, then extracts 2 times, Merge extracting solution, is condensed into pomegranate 18-36 parts of medicinal extract of extraction, by the aerial part of fresh dianthus superbus, impurity elimination is cleaned, in prefreezing - 30 DEG C of temperature, 1 drying time 3h take dianthus superbus by weight under conditions of 2 40 DEG C of drying temperatures after vacuum freeze drying 120-150 parts, pomegranate 18-36 parts of medicinal extract of extraction, mixing, drying and crushing sieve with 100 mesh sieve, and water is tuned into ball.
6. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1 or 2, it is characterised in that：The gallic acid 1-2 parts are extracted 15-30 parts of replacements of medicinal extract with myrobalan.
7. a kind of preparation process of anaesthetic that treating nose-nasosinusitis as claimed in claim 6, it is characterised in that：By weight It takes 75-150 parts of dryings of myrobalan and crushes, cross 80 mesh sieve, impregnate 30min and add 40 under conditions of temperature 60 C, power 300W Times 40% ethyl alcohol, ultrasonic extraction 60min obtain extracting solution, and the dregs of a decoction impregnate 15min, under the same terms, then extract 2 times, merging carries Liquid is taken, myrobalan is condensed into and extracts 15-30 parts of medicinal extract, by the aerial part of fresh dianthus superbus, impurity elimination is cleaned, in pre-freeze junction temperature- Under conditions of 30 DEG C, 1 drying time 3h, 2 times 40 DEG C of drying temperatures after vacuum freeze drying, dianthus superbus 120-is taken by weight 150 parts, myrobalan's 15-30 parts of medicinal extract of extraction, mixing, drying and crushing sieve with 100 mesh sieve, and water is tuned into ball.
8. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1 or 2, it is characterised in that：The bulk pharmaceutical chemicals are by weight It measures part and 50-75 parts of nutmeg, 50-75 parts of Rhododendron molle, 40-50 parts of fructus piperis longi, 40-50 parts of Fructus Forsythiae is added.
9. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1 or 2, it is characterised in that：The bulk pharmaceutical chemicals are by weight It measures part and 50-75 parts of root of Aucklandia lappa Decne, 120-150 parts of safflower, 50-75 parts of black cloud incense, 50-75 parts of rhizoma nardostachyos is added.
10. a kind of anaesthetic for treating nose-nasosinusitis according to claim 1 or 2, it is characterised in that：The bulk pharmaceutical chemicals are pressed Parts by weight be added 50-75 parts of radix aconiti agrestis, 50-75 parts of Moschus, 50-75 parts of Radix Ophiopogonis, when 50-75 parts of medicine.
CN201810484805.6A 2018-05-20 2018-05-20 A kind of anaesthetic and its preparation process for treating nose-nasosinusitis Pending CN108379327A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810484805.6A CN108379327A (en) 2018-05-20 2018-05-20 A kind of anaesthetic and its preparation process for treating nose-nasosinusitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810484805.6A CN108379327A (en) 2018-05-20 2018-05-20 A kind of anaesthetic and its preparation process for treating nose-nasosinusitis

Publications (1)

Publication Number Publication Date
CN108379327A true CN108379327A (en) 2018-08-10

Family

ID=63071158

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810484805.6A Pending CN108379327A (en) 2018-05-20 2018-05-20 A kind of anaesthetic and its preparation process for treating nose-nasosinusitis

Country Status (1)

Country Link
CN (1) CN108379327A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109142701A (en) * 2018-07-28 2019-01-04 江西师范大学 A kind of the anti-inflammatory activity detection method and application of Chinese azalea extract

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169750A (en) * 2013-03-14 2013-06-26 内蒙古医科大学 Ultrasonic extraction method for extracting flavone from dianthus superbus
CN107693682A (en) * 2017-10-21 2018-02-16 内蒙古民族大学附属医院 A kind of anaesthetic for treating sub- agate disease and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169750A (en) * 2013-03-14 2013-06-26 内蒙古医科大学 Ultrasonic extraction method for extracting flavone from dianthus superbus
CN107693682A (en) * 2017-10-21 2018-02-16 内蒙古民族大学附属医院 A kind of anaesthetic for treating sub- agate disease and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘圆等: "《中国民族药物学概论》", 30 November 2007, 四川民族出版社 *
刘金英等: "蒙药治疗鼻炎鼻窦炎30例临床观察 ", 《黑龙江医学》 *
周国燕等: "三七真空冷冻干燥工艺研究 ", 《中成药》 *
姜玉秋等: "没食子酸与环丙沙星联用对小鼠慢性鼻-鼻窦炎模型的作用 ", 《中国药科大学学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109142701A (en) * 2018-07-28 2019-01-04 江西师范大学 A kind of the anti-inflammatory activity detection method and application of Chinese azalea extract

Similar Documents

Publication Publication Date Title
CN102091203A (en) External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof
CN103861079B (en) Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors
CN103948732B (en) A kind of Chinese medicine composition treating allergic rhinitis
CN108324816A (en) A kind of anaesthetic and preparation method thereof for treating rheumatic arthritis
CN108379327A (en) A kind of anaesthetic and its preparation process for treating nose-nasosinusitis
CN105267811A (en) Externally-used granule treating manus and tinea pedis, and preparation method and application thereof
CN104474148A (en) Traditional Chinese medicine composition used for treating dermatomycosis and preparation method thereof
CN107550974A (en) Externally-applied medicinal composition of facial paralysis and application thereof
CN103705760B (en) A kind of suppository preparation method for postpartum perineum pain
CN105232759A (en) Pharmaceutical composition for rhinitis treatment and preparation method thereof
CN104958416A (en) Chinese medicinal preparation for treating sciatica and preparation method thereof
CN107397860A (en) A kind of anti-tumor biological Chinese medicine preparation and processing technology
CN114617939B (en) Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy
CN115120629B (en) Application of cord grass in preparing medicament for preventing/treating osteoarthropathy, and traditional Chinese medicine composition, traditional Chinese medicine preparation and preparation method thereof
CN114028483B (en) Pharmaceutical composition and preparation for treating chronic soft tissue injury
CN102784355A (en) First-aid drug and its preparation method
CN100406035C (en) Chinese medicine preparation for treating protrasion of lumbar intervertebral disc
CN105079404A (en) External traditional Chinese medicinal lotion for treating infective wound caused by multi-drug resistant bacteria
CN109908111A (en) A kind of rhinitis plaster and preparation method thereof
CN104815132A (en) External lotion for treating low back and leg pain and preparation method
CN105381177A (en) External use traditional Chinese medicine for treating sweet stains
CN107582792A (en) A kind of oral traditional Chinese medicine granule and preparation method for treating Child trauma fracture early stage swelling and pain
CN108524589A (en) A kind of Traditional Chinese medicine tincture for killing virus
CN106955326A (en) A kind of Chinese medicine composition and its utilization
CN107158238A (en) Medicine for treating acne and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180810